Michael M C Lo

Title: Michael M C Lo: Innovator in Bombesin Receptor Modulation

Introduction

Michael M C Lo is a notable inventor based in Edison, NJ (US). He has made significant contributions to the field of pharmacology, particularly in the development of novel compounds that target specific receptors in the human body. His work focuses on addressing critical health issues such as obesity and diabetes.

Latest Patents

Michael M C Lo holds a patent for "Substituted imidazole as bombesin receptor subtype-3 modulators." This patent describes certain novel substituted imidazoles that act as ligands for the human bombesin receptor, specifically targeting the bombesin receptor subtype-3 (BRS-3). These compounds are particularly valuable for the treatment, control, or prevention of diseases and disorders that can be managed through the modulation of BRS-3.

Career Highlights

Michael is currently employed at Merck Sharp & Dohme Corporation, a leading global healthcare company. His role involves research and development of innovative therapeutic solutions that can improve patient outcomes. His expertise in receptor modulation has positioned him as a key player in the pharmaceutical industry.

Collaborations

Throughout his career, Michael has collaborated with esteemed colleagues, including David Chen and Christopher L Franklin. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Michael M C Lo's contributions to the field of receptor modulation exemplify the impact of innovative thinking in addressing significant health challenges. His work continues to pave the way for advancements in therapeutic solutions for obesity and diabetes.